Home/Filings/4/0001415889-24-024046
4//SEC Filing

ENRIGHT PATRICK G 4

Accession 0001415889-24-024046

CIK 0001709941other

Filed

Sep 26, 8:00 PM ET

Accepted

Sep 27, 4:26 PM ET

Size

12.1 KB

Accession

0001415889-24-024046

Insider Transaction Report

Form 4
Period: 2024-09-25
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-09-25+15,00015,000 total
    Exercise: $18.00Exp: 2034-09-24Common Stock (15,000 underlying)
  • Conversion

    Series D Preferred Stock

    2024-09-275,848,6370 total(indirect: Longitude Venture Partners IV, L.P.)
    Common Stock (1,310,589 underlying)
  • Conversion

    Common Stock

    2024-09-27+1,310,5891,310,589 total(indirect: Longitude Venture Partners IV, L.P.)
  • Purchase

    Common Stock

    2024-09-27$18.00/sh+400,000$7,200,0001,710,589 total(indirect: Longitude Venture Partners IV, L.P.)
Footnotes (3)
  • [F1]Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date.
  • [F2]These shares are directly held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to exercise voting and investment discretion with respect to securities held by LVP IV. The reporting person and Ms. Juliet Tammenoms Bakker serve as the managing members of LCP IV and may be deemed to share voting and investment discretion with respect to securities held directly by LVP IV. Each of LCP IV, Mr. Enright, and Ms. Tammenoms Bakker disclaims beneficial ownership of such securities and this report shall not be deemed an admission that any of them is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F3]The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

Issuer

BioAge Labs, Inc.

CIK 0001709941

Entity typeother

Related Parties

1
  • filerCIK 0001253886

Filing Metadata

Form type
4
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 4:26 PM ET
Size
12.1 KB